-

SHAREHOLDER ALERT: Robbins LLP Investigates View, Inc. (VIEW) f/k/a CF Finance Acquisition Corp. II on Behalf of Shareholders

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP is investigating View, Inc. (NASDAQ: VIEW) to determine whether certain View officers and directors violated securities laws and breached their fiduciary duties to the Company. View manufactures smart building products that are purportedly designed to improve people's health, productivity, and experience while reducing energy consumption. Its primary product is a proprietary electrochromic glass panel that intelligently adjusts in response to the sun by tinting from clear to dark states, reducing heat and glare.

For more information about View, Inc.'s misconduct, click here.

View, Inc. (VIEW) May Have Misrepresented its Previously Disclosed Warranty Accruals

On November 30, 2020, CF Finance Acquisition Corp. II and View announced they had entered into a definitive merger agreement. On March 8, 2021, CF Finance Acquisition Corp. II and View combined via a business combination with View as the surviving public entity.

According to a class action complaint filed on behalf of purchasers of View, between November 30, 2020 and August 16, 2021, View stated that it had recorded a one-time warranty accrual of $24.5 million during the nine months ended September 30, 2019. On August 16, 2021, View announced it "began an independent investigation concerning the adequacy of the company's previously disclosed warranty accrual." On this news, the Company's share price fell $1.26, or over 24%, to close at $3.92 per share on August 17, 2021.

It appears that View had not properly accrued warranty costs related to its product and that there was a material weakness in View’s internal controls over accounting and financial reporting related to warranty accrual. As a result, View misstated its financial results.

View, Inc. (VIEW) shareholders have legal options. If you own shares of View, Inc. contact us for more information. All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:
Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against View, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Robbins LLP Urges GOSS Stockholders to Contact the Firm for Information About the Class Action Against Gossamer Bio, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Gossamer Bio, Inc. (NASDAQ: GOSS) securities between June 16, 2025 and February 20, 2026. Gossamer is a clinical stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension (PH) associated with interstitial lung disease.For more information, submit a form, email att...

Robbins LLP Urges IBRX Stockholders to Contact the Firm for Information About the Class Action Against ImmunityBio, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ImmunityBio, Inc. (NASDAQ: IBRX) securities between January 19, 2026 and March 25, 2026. ImmunityBio is a biotechnology company and ANKTIVA is the Company's lead biologic product. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. What is the class period? January 19, 2026 – March 25, 202...

Robbins LLP Reminds ALDX Investors of the Pending Class Action Lawsuit; Harmed Investors Should Contact the Firm for Information About Leading the Case Against Aldeyra Therapeutics, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) securities between November 3, 2023 and March 16, 2026. Defendant Aldeyra describes itself as a “biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated diseases.” Pertinent to this action is reproxalap, which is a novel reactive aldehyde species (RASP) inhib...
Back to Newsroom